Skip to main content

Table 3 Increase in the relative frequency (%) of different outcomes and the number needed to treat (NNT) with respective 95% CIs calculated using a normal approximation compared to the placebo. - Data were not reported in the studies. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

OutcomeASAS20ASAS40ASAS PR
Follow-up time (weeks)
12 to 162412 to 162412 to 1624
Drug%NNT (95% CI)%NNT (95% CI)%NNT (95% CI)%NNT (95% CI)%NNT (95% CI)%NNT (95% CI)
Infliximab [111]422.4 (1.9–3.2)352.9 (2.2–4.0)214.7 (3.7–6.7)
Etanercept [113, 119, 120, 123]273.7 (2.9–5.1)342.9 (2.2–4.3)185.5 (3.6–11.7)137.5 (3.7-∞)137.6 (4.9–16.9)
Adalimumab [126, 130, 131]273.7 (2.8–5.2)263.8 (3.0–5.2)263.8 (2.8–5.8)166.4 (4.8–9.5)176.1 (4.2–10.7)
Golimumab [133, 137, 138]372.7 (2.3–3.4)402.5 (2.1–3.2)283.6 (2.5–6.0)7.5 (4.8–16.3)
Certolizumab pegol [139]224.5 (3.0–9.1)283.6 (2.6–5.5)205.0 (3.7–7.5)
Secukinumab [142]362.8 (2.2–3.8)303.3 (2.5–4.6)128.1 (5.4–16.0)